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ABSTRACT 
Raloxifene, a selective estrogen receptor modulator (SERM), reduces fracture risk at least in part by 
improving the mechanical properties of bone in a cell- and estrogen receptor-independent manner. In 
this study, we determined that raloxifene directly interacts with the bone tissue. Through the use of 
multiple and complementary biophysical techniques including nuclear magnetic resonance (NMR) and 
Fourier transform infrared spectroscopy (FTIR), we show that raloxifene interacts specifically with the 
organic component or the organic/mineral composite, and not with hydroxyapatite. Structure-activity 
studies reveal that the basic side chain of raloxifene is an instrumental determinant in the interaction 
with bone. Thus, truncation of portions of the side chain reduces bone binding and also diminishes the 
increase in mechanical properties. Our results support a model wherein the piperidine interacts with 
bone matrix through electrostatic interactions with the piperidine nitrogen and through hydrophobic 
interactions (van der Waals) with the aliphatic groups in the side chain and the benzothiopene core. 
Furthermore, in silico prediction of the potential binding sites on the surface of collagen revealed the 
presence of a groove with sufficient space to accommodate raloxifene analogs. The hydroxyl groups on 
the benzothiophene nucleus, which are necessary for binding of SERMs to the estrogen receptor, are 
not required for binding to the bone surface, but mediate a more robust binding of the compound to 
the bone powder. In conclusion, we report herein a novel property of raloxifene analogs that allows 
them to interact with the bone tissue through potential contacts with the organic matrix and in 
particular collagen.  
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Introduction  
Bone is a crucial tissue that provides protection to internal organs and support, as well as the ability to 
respond to environmental signals by adapting its geometry and mass. This unique combination of 
stability and adaptability is made possible by the composition of the bone matrix itself, where the 
mineral phase, the hydroxyapatite, provides stiffness, and the organic phase, mainly composed by 
collagen, provides the tensile strength. Moreover, throughout an individual’s life, the bone matrix is 
constantly remodeled to meet metabolic and mechanical needs through the concerted effort of bone-
forming cells, the osteoblasts, and bone-resorbing cells, the osteoclasts.  
 Selective estrogen receptor modulators (SERMs) have been shown to decrease bone resorption and 
increase bone mineral density [1,2] through direct interaction with the estrogen receptors followed by 
tissue selective transcriptional regulation [3]. Raloxifene is a clinically-validated SERM, which has been 
shown to mimic the protective effect of estrogen on the skeletal system without triggering the 
proliferative effects of estrogen on the breast and endometrium of the uterus [4,5]. Many clinical 
studies have confirmed the therapeutic effectiveness of raloxifene in reducing the risk of vertebral 
fractures in postmenopausal osteoporosis patients by significantly slowing bone turnover, preventing 
bone loss, and maintaining the structural integrity of cancellous bone [6-9].   
The ability of raloxifene to reduce fracture risk is far greater than what would be predicted based solely 
on its effect on bone mineral density (BMD) [10,11]. Preclinical studies have documented that raloxifene 
leads to improved mechanical properties, most notably material-level toughness, despite little/no 
change in BMD or geometry/architecture [12-14]. Recent work has demonstrated that this effect of 
raloxifene is at least partly cell-independent [15]. Mechanistically, it has been proposed that raloxifene 
increases bound water within the matrix and this alters how strains are transferred between the organic 
and hydroxyapatite (HAP) portions of the matrix. Despite the biophysical evidence that this 
phenomenon is cell-independent, it remains unclear if this effect of raloxifene occurs through direct 
molecular interactions with bone and, if so, specifically what component of bone interacts with 
raloxifene.  
Because a mechanism that is independent of the bone cells and the estrogen receptor (ER) pathway 
activation could represent an unexpected pharmacological approach to reducing osteoporotic fractures, 
we aimed to identify the structural features within the benzothiophene nucleus of the raloxifene that 
are responsible for this compound’s interactions with bone tissue. We used multiple biophysical 
techniques including nuclear magnetic resonance (NMR) and Fourier transform infrared spectroscopy 
(FTIR) in order to quantify the interaction of benzothiophenes, estrogen and alendronate with bone and 
its components, and to investigate the molecular requirements that mediate that interaction.   
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 Materials 
Ceramic Hydroxyapatite (HAP) Type I, 20 µm, was from BioRad, Cat# 158-2000. 3D Collagen Culture 
System was from Millipore (Cat. No. ECM675). Poly D-Lysine 48-well plates used for the binding 
exposure studies were obtained from BIOCOAT (Cat. No. 354509, Lot No. 217048). DPBS (-Ca, -Mg) (Cat. 
No. 14-190-136) was from Fisher Scientific. Deuterated water (D2O) was from Sigma. SERMs (Table 1) 
were prepared as described [16,17]. The tested compounds were prepared as 10 mM solutions in 100 % 
DMSO or DMSO-d6 (Sigma Aldrich).   
Mechanical testing 
Skeletal tissue was obtained through a tissue sharing program at the Indiana University School of 
Medicine.  All animals were on protocols that were approved by the Institutional Animal Care and Use 
Committee prior to their use.  Femora from skeletally mature (15–24 mo/old) treatment naïve male 
hounds were machined into prismatic beams (N = 8–12 beams per experimental group) following the 
details described previously [15]. Beams were subjected to at least one freeze-thaw cycle to ensure 
eradication of cellular activity. Absence of any cellular activity after a single freeze-thaw was 
demonstrated by lactate dehydrogenase immunostaining of fresh and frozen-thawed bone and the 
results have been published in [15]. Specified compounds were dissolved in dimethyl sulfoxide (DMSO) 
and then added to incubation media (1X PBS with 1% penicillin-streptomycin supplementation) at a 2 
μM concentration. Solutions were changed every other day over the course of 2 weeks. Control bones 
were soaked in PBS with 0.04% DMSO vol/vol ratio.  At the conclusion of soaking, bone beams were 
subjected to four-point bending as previously described [15].  Energy to fracture was measured as the 
area under the force displacement curve. As these beams were machined to similar sizes, the parameter 
of energy to toughness is analogous to the modulus of toughness of the bone tissue as a material, 
described in previous work [15]. 
Brunauer, Emmett and Teller (BET) Isotherms 
Bone tissue from animals was ground using a mortar and pestle to produce a powder that was then 
sieved using a wire mesh to produce a distribution of differently-sized particles (< 0.3mm, >0.3 to 
<0.53mm, >0.53 to <0.86mm, and >0.86).  These batches were placed into 3/8 inch diameter tubes and 
purged with nitrogen for 2 hours at 40o C. The samples, equilibrated to room temperature, were 
analyzed with 7-point BET (partial pressures of 0.05 - 0.2) using a Micromeritics Tristar 3000 with 
nitrogen adsorbate to assess surface area [18]. The batch with sample particle size of < 0.3 mm failed 
the canonical acceptance criteria that require the plot of BET value versus P/Po to have the linear 
regression of r < 0.9975 due to an outlier in the data. This batch (<0.3 mm) was then tested on a 
Micromeritics ASAP 2020. Approximately 5 grams of this batch (<0.3 mm)  sample were placed into a 
1/2 inch diameter surface tube and purged with nitrogen at 60°C for approximately 6 hours. After 
equilibrating to room temperature, the sample was analyzed with a 7 point BET, as described above, 
using a Micromeritics ASAP 2020 with krypton adsorbate. The results met the acceptance criteria (r 
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>0.9975) and are reported as BET SSA (Specific Surface Area). Total surface area (TSA) is calculated by 
multiplying the BET SSA result by the sample weight.      
 
 Scanning Electron Microscopy (SEM)  
For SEM, powder samples were sprinkled on 13mm SEM stubs with carbon adhesive tabs using a 
stainless steel spatula. Stubs were then tapped to remove excess sample and sputter coated with Au:Pd 
(gold palladium 60:40) target. FEI 200 Quanta ESEM Imaging was conducted in low vacuum mode, at 
20kv, with 3.0 spot size and magnifications of 50-2500x. 
 
Energy Dispersive Spectroscopy (EDS)  
SEM/EDS imaging was performed to assess the size heterogeneity of the bone powder and determine 
the most appropriate particle size to be used in further experiments. Bone powder (<0.3 mm sample 
only) was rinsed gently with PBS (3X) and then divided into 2 batches. One batch was dried for 1 h in a 
vacuum oven at 37o C and then flushed with Argon. The other batch was air dried and flushed with 
Argon. Samples were sprinkled on 13mm SEM stubs with carbon adhesive tabs using a stainless steel 
spatula. Stubs were then tapped to remove excess sample, but they were not sputter coated. SEM/EDS 
imaging was conducted at 15-25kv, with magnifications of 30-500x using a FEI 200Quanta ESEM [19].  
 
Nuclear Magnetic Resonance (NMR) 
A modified version of a protocol previously described [20] was used. In this version, a quantitative 
measurement is obtained, by calculating the integral of the NMR signal, which is directly proportional to 
the concentration of the compound in solution. Solutions of compounds (50 µM) mixed in deuterated 
water (D2O) were divided into two equal aliquots. One aliquot (0.7 ml) was incubated with <0.3 mm 
bone powder (10 mg) or HAP (5 mg) in a 1.5 ml Eppendorf tube, for 1 h and 16 h under rotation at room 
temperature, while the other aliquot (0.7 ml) was incubated without bone powder or HAP, but 
maintained under rotation at room temperature. After incubation, samples were centrifuged at 1,000 g 
for 5 minutes and the supernatant was transferred to a new tube and frozen at -20°C until analysis. To 
evaluate binding to collagen, 3D collagen matrices (Merck-Millipore) were prepared following the 
manufacturer’s instructions and 0.2 ml of collagen was added to each well of a 48-well plate (Biocoat) 
and allowed to polymerize at 37°C. Incubations were performed with 0.7 ml of solution containing 50 
µM of compounds (raloxifene, 88074 and 189005) at 37°C for 1 h or 16 h. Control solutions were 
incubated in wells without polymerized collagen. After the indicated incubation times, solutions were 
aspirated with a pipette and stored at -20°C until analysis. All NMR data were obtained using a Bruker 
Avance III 600 MHz spectrometer equipped with a quadruple resonance (1H/19F/13C/15N) QCI CryoProbe.  
Spectra were acquired with a standard 1D proton sequence.  Residual water signals were suppressed 
with presaturation at a pulse power of 50 Hz during the relaxation delay.  A 1.7 s acquisition time and a 
2 s relaxation delay were used. The total number of transients ranged from 256 to 1024, with 4 dummy 
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scans.  The spectral width was 16 ppm.  All data were processed using the standard Bruker software 
(Topspin). The raw data were zero-filled to 64 k points and a 2 Hz line-broadening was applied before 
Fourier transformation.  
Fourier Transform Infrared Spectroscopy (FTIR) 
 The infrared spectrum of <0.3 mm bone powder alone, or bone powder exposed to 20 µM raloxifene 
for 1 h was recorded over the 400–4000 cm-1 range with a Thermo Nicolet 5700 FTIR spectrometer. For 
the actual measurements, after an exposure experiment (as described above), the supernatants were 
discarded and the matrices (bone powder, HAP, or Collagen) were washed (1X) with 1.5 ml of RO water, 
spun at 1000 g for 5 min and stored at -20o C.  These matrices were then ground with ultra dry KBr (2 mg 
sample/300 mg KBr) and thin pellets were obtained under vacuum. FTIR spectra were collected on these 
pellets.  The background and sample spectra were averaged over 50 scans and with a resolution of 2 cm-
1. 
Computational Methods 
Lowest-energy conformations of the compounds listed in Table 1 were determined using Spartan 14 
(Version 1.1.1, WAVEFUNCTION, Inc., Irvine, CA, USA), with a systematic search procedure using 
molecular mechanics force fields (MMFF). The conformation search was performed with the molecule in 
a fully relaxed state without any constraints or solvents. The lowest energy conformer (without further 
optimization) was used to compute the electrostatic surface potential and polar surface area. 
Exploratory binding site identification and docking to the collagen molecular surface were performed 
with Schrodinger Sitemap and Glide docking tools, (Schrödinger Drug Discovery Suite 2014-4, Maestro 
v10.0, Schrödinger, LLC, New York, NY, 2014). PDB xray accession codes 1Q7D and 1DZI were used for 
modeling purposes. 
Statistical Analysis 
Data are expressed as means ± standard deviation (SD) for each group. Statistics were calculated using 
SigmaPlot 12.3 (Systat Software, Inc., San Jose, CA USA). Statistical differences were evaluated with 
ANOVA (followed by post-hoc Dunnett’s or Student-Newman-Keuls tests) or t-test depending on the 
number of groups within an experiment. 
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RESULTS 
Binding of raloxifene to bone powder 
Fourier transform Infrared (FTIR) spectroscopy was used to assess the retention of raloxifene directly on 
the bone surface after bone powder was exposed to a solution containing the compound.  As 
topographical features of bone particles could play a role in the surface interaction with small 
molecules, we assessed various sizes of particles to scale the specific surface area available for the drug-
bone surface interaction. Decreasing the micro structural heterogeneity of the bone powder is essential 
to maintain a uniform surface area for surface reactivity studies [21-23]. In addition, the adsorbent 
properties are functionally dependent on the particle size. Therefore, a seven-point BET (Braunauer, 
Emmett and Teller Isotherms) was performed to determine the total surface area (TSA) and Specific 
Surface Area (SSA), of the particles on 4 samples of bone powder representing 4 different particle sizes: 
< 0.3mm, >0.3 to <0.53mm, >0.53to <0.86mm, and >0.86. The BET analysis revealed that particles 
smaller than 0.3 mm had a higher surface area (Supplementary Table 1). Since more exposed surface 
area can provide more interaction sites for the compound adsorption, the bone powder composed of 
<0.3 mm particles was used for all subsequent studies. Qualitative evaluation of the particles’ surface by 
Scanning Electron Microscopy (SEM) illustrates that micro structural heterogeneity is reduced in smaller 
sized particles (Supplementary Fig. 1).  
To assess binding of raloxifene to bone powder, FTIR spectra were recorded on samples of bone powder 
(<0.3 mm size) exposed to 20 µM raloxifene for 1 h (Fig. 1).  In comparison to the untreated bone 
powder (Fig. 1A) that showed a broad feature-less spectrum, raloxifene-exposed bone samples showed 
additional vibration bands in the fingerprint region 1380- 1650 cm-1 (Fig. 1B). Specifically, these new 
bands were found at 1642, 1560, 1540, 1465, 1384, 1093, 1034, 602 and 564 cm-1. The weak 1642 band 
likely arose from SP2 C=C stretch. The inhomogeneous broad peak in the region 3434 cm-1 indicated the 
presence of exchangeable protons while the homogeneous sharper peaks in the fingerprint region 
pointed to a possible crystalline nature of an adsorbed compound [24-27]. The spectra of a neat solution 
of 20 µM raloxifene without bone powder is shown as reference (Fig. 1C). Although qualitative, the 
changes in the infrared spectra of the bone powder when incubated with raloxifene suggest that 
raloxifene is retained on the bone surface.  
  
7 
 
 
 Figure 1 
 
Analogs for structure-activity studies 
To explore the structural requirements responsible for the potential interaction of raloxifene with bone, 
a set of raloxifene analogs was chosen in which the central substructure of raloxifene was systematically 
modified. These analogs are shown in Table 1. Compound 189005 is the methyl ether derivative of 
raloxifene at the 6-position of the benzothiophene, a structural modification that results in >100-fold 
reduction in the affinity of the molecule for the estrogen receptor [16]; in analog 88074 the basic side 
chain is absent; 173468 lacks both hydroxyl groups at the 6- and 4’-positions; and compound 153546 is a 
minimal aryl benzothiophene fragment lacking the entire basic side chain. These modifications 
systematically impact the lipophilic character of the benzothiophene, as indicated by the differences in 
the polar surface area (PSA) which is the sum of surfaces of polar atoms (oxygens, nitrogens and 
hydrogens).  The PSA values for this subset of raloxifene analogs spans from 72 Å2 (compound 88074) to 
24 Å2 (compound 173468).  Compounds harboring the highest number of –OH groups were the ones 
with higher PSA (Table 1).  The calculated logP and logD (Table 1) of this series of compounds 
corroborate a trend that is consistent with the PSA values. 
To determine the effect of these analogs on bone mechanical properties, dog beams (12-15 beams from 
4 different dogs) were soaked for 2 weeks with each compound at the concentration of 2 µM, followed 
by mechanical testing by 4-point bending.  Energy absorption to fracture, the property that best 
expresses the mechanical effects of raloxifene on bone in these in vitro soaking experiments, was 25% 
higher in beams that were treated with 189005 compared to DMSO-soaked control beams (Table 1).  
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The remaining 6 compounds elicited an effect that was either equivalent to or lower than DMSO 
controls.    
 
 
 
 
Table 1 
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Binding of raloxifene analogs to bone powder, collagen and hydroxyapatite 
NMR spectroscopy was used to quantify the amount of compound remaining in solution after incubation 
with bone powder and the primary component of bone, HAP or type I collagen. In this assay, if 
interaction occurs, the amount of compound retrieved from the supernatants after incubation with 
bone is diminished, an indication that some of the compound is retained in the matrix.  
The ability of raloxifene to interact with bone powder was first tested by solution state 1H NMR.  In 
addition to raloxifene, compounds 88074 and 189005 were tested to compare the relative contributions 
of the hydroxyl groups (e.g. in 189005) and of the side chain (e.g. in 88074) to bone binding. Incubation 
of 50 µM raloxifene with 10 mg of bone powder for 1 h, 4 h and 8 h resulted in a statistically significant 
decrease of raloxifene signal in the recovered supernatants compared to the signal present in control 
solution that has not been exposed to bone powder (Fig. 2A).  These results indicate retention of 
raloxifene by the bone sample.  The methoxy analog of raloxifene, 189005, bound in a similar manner to 
raloxifene, with the signal almost completely disappeared from the supernatant (Fig. 2C). In contrast, 
the analog lacking the basic side chain (88074) also had reduced signal in the supernatant, but the 
magnitude of the signal intensity drop was lower compared to that observed for raloxifene (Fig. 2B).  
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Figure 2 
 
To assess whether the organic constituent of bone might be retaining these compounds, we incubated 
50 µM of raloxifene with a commercially available tri-dimensional collagen matrix composed exclusively 
of collagen 1a1.  Incubation with the collagen matrix for 1 h, 4 h or 8 h resulted in a statistically 
significant reduction in the NMR signals of raloxifene compared to the control experiment, indicating 
binding of raloxifene to the collagen matrix (Fig. 3A). A similar result was observed in compound 189005 
(Fig 3B). On the other hand, the interaction of 88074 with collagen, although significant (Fig 3C), was 
less than the interaction found with the other 2 compounds.  
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Figure 3 
We then explored the bone binding properties of an array of direct analogs of raloxifene in order to 
investigate the specific structural features responsible for its unique activity (Fig. 4 and Table 2). In this 
set of experiments we also included incubations with the mineral component of bone, hydroxyapatite 
(HAP), which contributes 95 % of crystallinity to the mineral, in order to examine the surface 
interactions between HAP and the raloxifene analogs. Exposure of raloxifene to bone powder resulted in 
a 54.2% reduction in signal after 1 h and 99.0% reduction after 16 h of incubation (Table 2). On the other 
hand, incubation with hydroxyapatite did not elicit a decrease, but rather, it resulted in a unexpected 
increase in the amount of raloxifene recovered from the supernatants (Fig. 4); we hypothesize that this 
increase is due to an improvement in raloxifene solubility facilitated by the very charged HAP. 
Compound 88074 was also reduced after incubation with bone powder, but to a lesser extent than 
raloxifene (by 26.4% at 1 h and 34.1% at 16 h), while the reduction with HAP was minimal (13.3% and 
15.1% at 1 h and 16 h respectively).  
To gain a better understanding of the role played by the hydroxyl (OH) groups in the interaction with the 
bone samples, we investigated three additional compounds: 173468, which lacks hydroxyl groups at the 
4’- and 6-positions, 153546, which comprises only the aryl benzothiophene core, and 17b-estradiol. The 
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signal from compound 173468 was not reduced after 1 h of incubation with bone powder, whereas it 
was decreased by about 89% after 16 h, while exposure to HAP did not elicit a significant reduction in 
the recovered signal. Interestingly, the minimal fragment 153546 showed only a small ability to be 
retained by bone powder, with a 42.8% and 46.4% reduction in signal after 1 h and 16 h in the presence 
of bone powder (Fig. 4 and Table 2). Moreover, we included incubations of HAP and bone powder with 
Alendronate, a well-known bisphosphonate that was shown to bind avidly to both matrices. The 
comparison between the percent drop in NMR signal with each compound and Alendronate in the 
presence of bone powder reveals that Raloxifene binds as avidly as Alendronate to bone powder. In 
addition, while Alendronate is completely sequestered by HAP at 16 h, incubations of raloxifene with 
HAP did not show any decrease, further confirming that the ability of raloxifene to bind bone powder 
relies on its interaction with the organic portion of the bone matrix and not with the mineral phase. The 
interaction of raloxifene analogs with bone powder is specific, as shown by the lack of NMR signal drop 
in supernatants containing the compound 3103672, a GPCR agonist with sufficient structural diversity 
from raloxifene to be used as an appropriate negative control (Fig. 4 and Table 2). 
 
Figure 4 
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Table 2 
DISCUSSION AND CONCLUSIONS 
We hypothesized that the binding profile to bone matrix and its components may shed light into the 
mechanism of action of raloxifene on osteoporosis pharmacology. The analogs we investigated are a 
systematic truncation of the parent structure in order to provide a broad range of structural diversity 
within the scaffold. It included variations in the phenol groups on the benzothiophene core, in order to 
rule out ER-mediated events, and modifications of the basic side chain. The results indicate that 
benzothiophene-derived SERMs can interact with bone matrix in a structure-dependent manner. 
Moreover, this interaction appears to be only with the organic component or the organic/mineral 
composite, as it does not exist with pure hydroxyapatite.   
Previous studies have established that the structural features critical for the ER mediated pharmacology 
of raloxifene are the hydroxyl substituent at the 6- and, to a lesser extent, the 4’-positions of the 
benzothiopene core. Structure activity relationship (SAR) studies have shown that raloxifene-like 
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compounds where the 6- and/or 4’-hydroxyl groups are absent or are capped as methyl ethers show a 
several fold decrease in the relative binding affinity to the ER [16,17].   
Compared to the essential role played by the hydroxyl groups (-OH) in binding the ER, it appears that 
they play an attenuated role in modulating the physical interactions with bone. For example, compound 
173468 lacks the -OH groups on the 6- and 4’-positions and has a Ki to the ER’s of > 10 µM. In 
comparison, raloxifene binds with a Ki of 0.43 nM to ERalpha and 4.3 nM to ERbeta. Yet compound 
173468 is shown here to retain bone matrix binding activity, with a magnitude comparable to that of 
raloxifene. In contrast, compound 153546 binds with high affinity to ER alpha and beta with Ki’s of 4.1 
and 2.3 nM, respectively, yet demonstrates very low binding to bone powder or HAP (Fig. 4). Taken 
together, these data indicate that the structural requirements for bone matrix binding differ from the 
ones needed to bind the estrogen receptor. However, the phenolic groups may be responsible for a 
more robust binding of the compound to the bone powder that allows greater binding at the earlier 
time point. Thus, while raloxifene signal decreases by 54.2% already after 1 h of incubation with bone 
powder, 173468 signal does not change, although the two compounds display a comparable decrease at 
16 h. 
The basic side-chain appears to be a crucial structural requirement for bone matrix binding. This is 
illustrated by SAR studies of the basic side chain in which portions of this component have been 
sequentially truncated. Removal of the aminoethylpiperdine moiety, as in 88074, reduces bone binding, 
compared to raloxifene. Further truncation of the entire aroyl side chain, as in 153546, also results in 
reduced interaction of the compound with bone powder (Fig. 4). The importance of the basic side chain 
was further assessed using the molecular modeling software SiteMap (SiteMap, version 3.0, 
Schrodinger, LLC, New York, NY, 2014) and crystallographic structures (PDB accession codes 1Q7D and 
1DZI) to search for potential binding sites on the surface of collagen.  The sitemap obtained for both the 
triple fibril helix and collagen complexed with an integrin indicated a groove with sufficient space to 
accommodate raloxifene analogs.  This groove is rich in acidic glutamate residues which is consistent 
with affinity for the basic side chain. A high resolution model image of a collagen triple chain fiber 
molecular surface (Fig. 5, top panel) shows the putative binding site as small white spheres. A second 
closer view (Fig. 5, bottom panel) shows 189005 docked from two different angles. This pose highlights 
two polar interactions, the piperidine basic-N interacting with E12 of orange chain and the pendant 
phenolic OH interacting with E12 on blue chain. The benzothiophene core is stacking with F9 (blue 
chain) in a hydrophobic interaction. It is also proposed that the benzothiophene could have a second 
hydrophobic interaction with an adjacent triple chain fiber. Thus, in this model, there are important 
polar interactions between raloxifene and one triple chain collagen fiber (basic N and phenol OH) but 
additionally hydrophobic interactions between the benzothiophene ring and F9 and possibly other 
collagen triple chain fibers in adjacent positions. 
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Figure 5 
At the molecular level, raloxifene and the analogs evaluated in this study could interact with bone 
matrix through two types of surface interactions: i) hydrophilic or electrostatic interactions via the 
piperidine nitrogen, and/or ii) hydrophobic interactions (van der Waals) via the aliphatic carbons and 
aromatic rings of  the benzothiophene core, the tether to the basic nitrogen, and the methylene groups 
of the piperidine ring. Our finding that the side chain is required for bone matrix binding could be 
explained by a combination of electrostatic interactions by the piperidine nitrogen and of an important 
role of the hydrophobic regions. Compound 189005, having the lowest PSA (50.8 Å), cLogP (7.254) and 
cLogD (5.49) (Table 1), and hence a greatest proportion of hydrophobic surface, supports this 
hypothesis, as it was retained by bone powder and collagen with highest efficiency. The hydrophobic 
regions (green colored) of raloxifene and 189005 are large and extend throughout the molecule (Fig. 6).  
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Figure 6
In contrast, 88074 has a higher PSA (72.9 Å), cLogP (5.106), and cLogD(4.88). It contains no basic side 
chain and has fewer aliphatic groups than 189005. Thus, it is significantly less hydrophobic and 
correspondingly less able to take advantage of both the electrostatic interactions imparted by the basic 
nitrogen and the van der Waals contacts with the organic phases of the bone matrix. This reduced 
hydrophobicity is consistent with the reduced bone and collagen binding when comparing 88074 to 
189005. Our data indicate that the interaction of the raloxifene analogs with bone is due to a 
combination of intrinsic structural features. The basic nitrogen in the piperidine side chain appears to be 
the dominant feature. However, the hydrophobic regions and the –OH groups play an important role as 
well. The interaction of compounds with the bone surface has historically been predominantly 
electrostatic, as in the case of tetracyclines, calcein, and bisphosphonates, and has involved the mineral 
phase rather than the organic phase. Bisphosphonates, in particular, have been shown to bind avidly to 
HAP using a NMR assay similar to the one used in this paper [20]. However, our data suggest that the 
hydrophobic interactions are potentially another important way to induce greater molecule–surface 
affinity and that they occur through the organic phase (especially collagen) rather than the 
hydroxyapatite.
To determine if the bone binding data correlated to a functional effect on bone strength, we tested 
raloxifene, 88074 and 189005 for their ability to affect bone material toughness using an ex-vivo 
methodology previously described [15].  Soaking of dog bone beams in raloxifene and 189005 resulted 
in a similar enhancement in toughness while 88074 did not elicit an increase (Table 1).  These data are 
consistent with the bone binding data for these compounds.     
The biophysical techniques described in this manuscript allowed us to determine the previously 
unknown ability of raloxifene to bind bone matrix. However, the experimental methodology cannot 
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distinguish between passive, non-specific compound deposition (or retention), and specific binding to 
the tested surface. Moreover, the 3D collagen fibrillar matrix employed in our experiments does not 
reproduce the conformation of the collagen fibers in bone and does not allow a direct comparison of the 
amount of collagen present in the 3D matrix with that present in the bone powder.  
Taken together, the data provide evidence that raloxifene, and select analogs, have the ability to bind 
bone matrix in an unexpected fashion. Raloxifene does not effectively interact with the mineral phase of 
bone, but rather interacts with the organic portion potentially through hydrophobic interactions.  We 
propose that the binding of benzothiophene SERMs to bone depends on the combination of the 
hydroxyl groups at the 6- and 4’- positions, the basic amino side-chain and the intrinsic aliphatic 
character. Of these groups, the basic amino group is the primary determinant of bone binding. Given 
that other bone active SERMs, such as tamoxifen, contain a basic side chain, it would be interesting to 
determine if it also affects bone toughness.  Additional studies are required to clarify if these structural 
motifs could be transferable to generate new chemical entities for the improvement of bone mechanical 
properties.  
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Figure and Table legends 
Figure 1. Detection of adsorbed raloxifene on the bone powder by FTIR. In comparison to bone powder 
that has never been in contact with raloxifene (A), bone exposed to 50 µM raloxifene for 1 h shows rich 
fingerprint region at 1380- 1650 cm-1 (B). Incubation with raloxifene results on the appearance of new 
sharper  bands at 1642, 1560, 1540, 1465, 1384, 1093, 1034, 602 and 564 cm-1 similar to the bands in 
the neat spectrum raloxifene alone (C). The sharper peaks in B reflect crystalline nature of the adsorbed 
species as against the broad (hence glassy) bands observed in the bone powder matrix (C). 
Table 1. Tested compounds and their structural features. Polar Surface Area (PSA) is calculated from the 
lowest energy conformation, (using MMFF). cLogP is from BioByte, (Claremont, CA). cLogD@pH 7.4 is 
from ChemAxon, (Cambridge, MA).  Red boxes enclose critical structural features of the compounds. 
Figure 2. Detection and relative quantification of raloxifene and its analogs in supernatants after 
incubation with bone powder by NMR. 1H NMR spectra (0 – 8 ppm range) of 50 μM raloxifene (A), 
88074 (B) and 189005 (C) incubated with and without 10 mg of dog bone powder for 1 h, 4 h or 8 h.  
Graphs represent the integral of the peaks. Bars are mean ± s.d. N=3; *p<0.05 by t-test vs control at the 
same time point. BP: bone powder 
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Figure 3. Detection and relative quantification of raloxifene and its analogs in supernatants after 
incubation with collagen by NMR. (A) 1H NMR spectra (0 – 8 ppm range) of 50 μM raloxifene. NMR 
spectra of 189005 (B) and 88074 (C) incubated with and without 0.5 ml of polymerized 3D collagen 
matrix. Graphs represent the integral of the peaks. Bars are mean ± s.d. N=3; *p<0.05 by t-test vs control 
at the same time point.  (D) Representative NMR spectra of a solution of raloxifene after incubation with 
collagen (top three) and a control solution (bottom three) that highlights the marked difference in the 
height of the peaks between the two conditions. Each spectrum represents a supernatant obtained from 
separate incubations.  
Figure 4. Detection and quantification of raloxifene and its analogs in supernatants after incubation with 
bone powder by NMR. Quantification of residual raloxifene, 88074, 173468, 153546, 17beta-estradiol, 
alendronate and 3103672 after incubation of a 50 µM solution of each compound with 10 mg of bone 
powder and 5 mg of HAP for 1h or 16 h. Bars represent fold change relative to control. HAP: 
hydroxyapatite; BP: bone powder. N=2. 
Table 2. Results presented in Figure 4, expressed as % decrease relative to control (top portion of the 
table) and % decrease relative to alendronate (bottom portion). HAP: hydroxyapatite; BP: bone powder.  
Figure 5. Top panel: collagen triple chain fiber molecular surface with putative binding site (near the 
center) indicated with small white spheres, surface colored by underlying atom-type. PDB code= 1Q7D. 
Bottom panel: two views turned 90 degrees from each other, show 189005 docked to the putative site, 
showing two polar interactions, the piperidine basic-N interacting with E12 of orange chain and the 
pendant phenolic OH interacting with E12 on blue chain. The benzothiophene core is stacking with F9 
(blue chain). 
Figure 6. Electrostatic Potential on an Electron Density Isosurface corresponding to a van der Waals 
Surface of raloxifene, 88074 and 189005. Representation of the hydrophobic regions (green colored). 
Supplementary Table 1. Characterization of bone powder particles. BET SSA: Specific Surface Area, 
measured by Braunauer, Emmett and Teller (BET) Isotherms. 
Supplementary Figure 1. Representative images of bone powder preparations obtained by SEM. Images 
were collected at 50X. 
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